文献速递创伤与烧伤重症综合管理与镇静镇痛

消除苯二氮䓬:以保留苯二氮䓬策略预防和治疗酒精戒断综合征

Eliminating the benzos: A benzodiazepine-sparing approach to preventing and treating alcohol withdrawal syndrome.
PubMed 文献 · J Trauma Acute Care Surg · 2023-11-07
一句话结论创伤患者采用以加巴喷丁和可乐定为主的保留苯二氮䓬方案预防和治疗酒精戒断综合征安全,可降低每日最高CIWA-Ar评分并显著减少苯二氮䓬用量。

该研究在学术性一级创伤中心比较了保留苯二氮䓬方案实施前(常规组387例)后(保留苯二氮䓬组134例)有酒精戒断风险的创伤患者。保留苯二氮䓬方案主要使用加巴喷丁和可乐定。结果显示保留苯二氮䓬组每日最高CIWA-Ar评分更低(2.7 vs 1.5,p=0.04),每日劳拉西泮当量显著更低(1.1 vs 0.2,p<0.01),而每日吗啡毫克当量无差异(31.5 vs 33.6,p=0.49),住院时间、ICU时间和呼吸机天数无差异。作者认为该方案在创伤患者中安全,未来将关注避免酒精戒断综合征和苯二氮䓬使用对结局的影响。

要点

  • 保留苯二氮䓬方案主要使用加巴喷丁和可乐定,用于有酒精戒断风险的创伤患者。
  • 保留苯二氮䓬组每日最高CIWA-Ar评分低于常规组(2.7 vs 1.5,p=0.04)。
  • 保留苯二氮䓬组每日劳拉西泮当量显著低于常规组(1.1 vs 0.2,p<0.01)。
  • 两组每日吗啡毫克当量无差异(31.5 vs 33.6,p=0.49),住院时间、ICU时间和呼吸机天数无差异。
  • 作者认为该保留苯二氮䓬方案在创伤患者中安全。

适用人群与场景

  • 入院时被识别为有酒精戒断风险的创伤患者,收治于学术性一级创伤中心。
  • 比较方案实施前(常规组387例)和实施后(保留苯二氮䓬组134例)的患者。

处置流程与药物剂量

  • 保留苯二氮䓬方案主要使用加巴喷丁和可乐定,用于预防和治疗酒精戒断综合征。

研究设计与关键结果

  • 研究类型为在学术性一级创伤中心开展的方案实施前后比较,常规组387例,保留苯二氮䓬组134例。
  • 损伤严重度评分(13 vs 16,p=0.10)和入院酒精水平(99 vs 149,p=0.06)两组相似。
  • 保留苯二氮䓬组每日最高CIWA-Ar评分低于常规组(2.7 vs 1.5,p=0.04)。
  • 每日吗啡毫克当量两组无差异(31.5 vs 33.6,p=0.49)。
  • 每日劳拉西泮当量保留苯二氮䓬组显著低于常规组(1.1 vs 0.2,p<0.01)。
  • 住院时间和呼吸机天数两组无差异。

证据类型、等级与局限

  • 证据类型:治疗/护理管理研究,证据等级Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在创伤患者中实施主要使用可乐定和加巴喷丁的保留苯二氮䓬方案来预防和治疗酒精戒断综合征是安全的,可降低每日最高CIWA-Ar评分并显著减少苯二氮䓬的需求。
  • 未来研究将关注避免酒精戒断综合征和苯二氮䓬使用对创伤人群结局的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Alcohol withdrawal syndrome (AWS) represents significant cost to the hospitalized trauma population from a clinical and financial perspective. Historically, AWS has been managed with benzodiazepines. Despite their efficacy, benzodiazepines carry a heavy adverse effect profile. Recently, benzodiazepine-sparing protocols for the prophylaxis and treatment of AWS have been used in medical patient populations. Most existing benzodiazepine-sparing protocols use phenobarbital, while ours primarily uses gabapentin and clonidine, and no such protocol has been developed and examined for safety and efficacy specifically within a trauma population.

METHODS: In December of 2019, we implemented our benzodiazepine-sparing protocol for trauma patients identified at risk for alcohol withdrawal on admission. Trauma patients at risk for AWS admitted to an academic Level 1 trauma center before (conventional) and after (benzodiazepine-sparing [BS]) protocol implementation were compared. Outcomes examined include morphine milligram equivalent dosing rates and lorazepam equivalent dosing rates as well as the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) scores, hospital length of stay, intensive care unit length of stay, and ventilator days.

RESULTS: A total of 387 conventional and 134 benzodiazepine sparing patients were compared. Injury Severity Score (13 vs. 16, p = 0.10) and admission alcohol levels (99 vs. 149, p = 0.06) were similar. Patients in the BS pathway had a lower maximum daily CIWA-Ar (2.7 vs. 1.5, p = 0.04). While mean morphine milligram equivalent per day was not different between groups (31.5 vs. 33.6, p = 0.49), mean lorazepam equivalents per day was significantly lower in the BS group (1.1 vs. 0.2, p < 0.01). Length of stay and vent days were not different between the groups.

CONCLUSION: Implementation of a benzodiazepine-sparing pathway that uses primarily clonidine and gabapentin to prevent and treat alcohol withdrawal syndrome in trauma patients is safe, reduces the daily maximum CIWA-Ar, and significantly decreases the need for benzodiazepines. Future studies will focus on outcomes affected by avoiding AWS and benzodiazepines in the trauma population.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. McCullough MA, Miller PR, Martin T, et al. Eliminating the benzos: A benzodiazepine-sparing approach to preventing and treating alcohol withdrawal syndrome. J Trauma Acute Care Surg. 2023. PMID: 37934662. doi:10.1097/TA.0000000000004188

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。